Benufutamab
Product Specifications
UNSPSC Description
Benufutamab (GEN1029) is a death receptor 5 (DR5)-specific agonistic antibody. Benufutamab is a mixture of 2 noncompeting DR5-specific IgG1 antibodies, each with an E430G mutation in the Fc domain. Benufutamab has antitumor effects[1].
Target Antigen
Apoptosis; TNF Receptor
Type
Inhibitory Antibodies
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/benufutamab.html
Purity
98.62
Solubility
10 mM in DMSO
Smiles
[Benufutamab]
References & Citations
[1]Hilma J van der Horst, et al. Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2165-2172. |[2]Marije B Overdijk, et al. Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism. Mol Cancer Ther. 2020 Oct;19(10):2126-2138.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99470/Benufutamab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99470/Benufutamab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2109730-69-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Cucurbit[7]uril](https://cdn.genprice.uk/genprice/genprice2.png)
![Cucurbit[7]uril](https://cdn.genprice.uk/genprice/genprice5.png)